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3D DESI‑MS lipid imaging 
in a xenograft model 
of glioblastoma: a proof of principle
Fiona Henderson1,2, Emrys Jones3, Joanna Denbigh4, Lidan Christie1, Richard Chapman3, 
Emmy Hoyes3, Emmanuelle Claude3, Kaye J. Williams1,2, Federico Roncaroli5 & 
Adam McMahon1*
Desorption electrospray ionisation mass spectrometry (DESI‑MS) can image hundreds of molecules 
in a 2D tissue section, making it an ideal tool for mapping tumour heterogeneity. Tumour lipid 
metabolism has gained increasing attention over the past decade; and here, lipid heterogeneity 
has been visualised in a glioblastoma xenograft tumour using 3D DESI‑MS imaging. The use of an 
automatic slide loader automates 3D imaging for high sample‑throughput. Glioblastomas are highly 
aggressive primary brain tumours, which display heterogeneous characteristics and are resistant to 
chemotherapy and radiotherapy. It is therefore important to understand biochemical contributions to 
their heterogeneity, which may be contributing to treatment resistance. Adjacent sections to those 
used for DESI‑MS imaging were used for H&E staining and immunofluorescence to identify different 
histological regions, and areas of hypoxia. Comparing DESI‑MS imaging with biological staining 
allowed association of different lipid species with hypoxic and viable tissue within the tumour, and 
hence mapping of molecularly different tumour regions in 3D space. This work highlights that lipids 
are playing an important role in the heterogeneity of this xenograft tumour model, and DESI‑MS 
imaging can be used for lipid 3D imaging in an automated fashion to reveal heterogeneity, which is 
not apparent in H&E stains alone.
The revised 4th edition of the classification edited by the World Health Organisation (WHO) recognises more 
than 120 tumour entities with distinctive morphology, location, age distribution and biologic behaviour. Tumour 
entities are graded with a ‘malignancy scale’ that is intended to predict their natural biological behaviour. Gliomas 
account for the commonest primary brain tumours in adults. They are graded from I to IV based on histological 
features. The identification of molecular and genetic signatures such as mutations in the isocitrate dehydrogenase 
1 and 2 (IDH1/2) genes, ATRX and hTERT, CDKN2A/B deletions, EGFR gene amplifications and co-deletions 
of chromosomes 1p19q has improved the diagnostic accuracy and stratification of patients with glioma. Glio-
blastoma (GBM) (WHO grade IV) is the most aggressive among gliomas with a patients’ mean survival of 
15 months from  onset1. GBM can occur as a primary tumour or can result from the progression of a lower grade 
astrocytoma. Primary (de novo) GBM is the most common type accounting approximately for 90% of cases. Glio-
blastomas are highly heterogeneous tumours. Regional genetic, epigenetic and metabolic differences determine 
intratumoural heterogeneity. Intratumour heterogeneity is a result of evolutionary changes that occur following 
dynamic remodelling of the tumour microenvironment and the effects of  treatment2,3. These genetic alterations 
can contribute towards resistance to  therapy4. Among metabolic changes in GBM, lipid levels including free fatty 
acids are altered compared to normal  tissue5,6 as the result of hypoperfusion and subsequent  hypoxia7,8. Fatty 
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acid synthase (FASN) is responsible for de novo synthesis of fatty acids, and is upregulated in  gliomas9, amongst 
other cancer  types10,11, with an increase in expression being associated with malignant  gliomas12.
Gliomas are diagnosed and monitored with magnetic resonance imaging (MRI). Molecular imaging modali-
ties such as positron emission tomography (PET) can also contribute to the management of patients with glioma. 
Both MRI and PET have progressed substantially in investigating the heterogeneity of glial tumours as they can 
image whole tumours in-vivo13–15 but they may fail to detect subtle but relevant structural or functional features 
due to their low spatial resolution.
Mass spectrometry imaging is an ex-vivo molecular imaging method that offers advantages over PET and 
MRI because it can image hundreds of molecules at a spatial resolution below 200 μm. Desorption electrospray 
ionisation mass spectrometry (DESI-MS) is an ambient mass spectrometry technique which has been used 
for molecular imaging since  200416–18. Although DESI-MS is an ex-vivo technique, it causes minimal degrada-
tion to the sample, and so staining is possible on the same section post-DESI-MS imaging, making it an ideal 
tool for imaging brain tumours. Unlike in-vivo techniques such as PET or MRI, MS imaging only captures 2D 
images. However, MS imaging can acquire serial tissue sections, and stack as 3D images. Matrix-assisted laser 
desorption ionisation (MALDI-MS) imaging is the most commonly used MS imaging technique and has already 
been used for 3D  imaging19 including the mapping of drug distribution in  tumours20. Eberlin et al. reported 3D 
DESI-MS imaging of a mouse  brain21. 3D MS imaging is a lengthy process and involves human input to set up 
and acquire new images. Here, for the first time, an automated 3D DESI-MS imaging method has been used to 
visualise tumour heterogeneity.
A robotic slide loader that can autonomously mount and change slides on the DESI-MS instrument allows 
rapid acquisition of a set of 2D images that are automatically processed and aligned to render a 3D image. This 
enables straightforward and rapid generation of 3D DESI-MS images. DESI-MS is an excellent tool for the 
detection of lipids, and has been used in numerous lipidomic studies in  cancer22–24. In gliomas, DESI-MS lipid 
fingerprints could distinguish between healthy and tumour tissue and between different glioma  grades25,26.
In this study we performed 3D DESI-MS imaging using a heterotopic xenograft glioblastoma model to inves-
tigate lipid heterogeneity and immunofluorescence to find correlations between the MS lipid heterogeneity data 
and the downstream marker of hypoxic signalling, carbonic anhydrase-9 (CA-9).
Results and discussion
Fifteen sections were taken every 120 μm from each GBM xenograft and underwent DESI-MS imaging in both 
negative and positive ion mode. The 2D data were combined and reconstructed to generate 3D DESI-MS images 
for both polarities. Multivariate analysis (MVA) was performed on the 3D data set to reveal areas of the tumour 
which had different regions according to their lipid profiles (Fig. 1). 3D DESI-MS imaging was therefore able to 
visualise areas of distinct lipid heterogeneity within the tumour.
2D images of representative peaks from the distinct tumour areas as separated by the MVA is shown in Fig. 2. 
A peak appearing in negative ion mode at m/z 885 has been tentatively identified as PI (38:4) based on exact mass 
and what has previously been reported in the literature, with Eberlin et al. also reporting m/z 885 (PI 38:4) in 
viable  GBM25. Sections adjacent to those used for DESI-MS were stained with CA-9 (to visualise hypoxic regions) 
and H&E, these were interpreted by a neuropathologist. Molecularly different regions visualised in the DESI-MS 
images showed different cellularity, with hypoxic regions appearing less cellular than the remaining tumour.
Comparing DESI-MS images with CA-9 staining (Figs. 3 and 4) revealed that the peaks at m/z 400 and m/z 
428 (positive ion mode) co-localise with areas of lower cellularity (shown as blue in Fig. 3). The peaks at m/z 
Figure 1.  3D DESI-MS images of molecularly distinct regions (displayed in different colours) as revealed by 
multivariate analysis. Each frame shows a different 2D perspective as the 3D image is rotated. A1–A4: positive 
ion images, B1–B4: negative ion images.
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Figure 2.  DESI-MS images in positive (A) and negative (B) ion mode of peaks reflecting molecularly different 
regions.
Figure 3.  2D DESI-MS images in positive ion mode showing lipids that localise in different regions of the 
tumour (left), with corresponding CA-9 stains (middle), and H&E images (right) for different sections of the 
GBM.
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400 and m/z 428 co-localised with hypoxia but only in some hypoxic regions forming a thin band within the 
areas of CA-9 staining. The m/z 400 and 428 band was overlaid with CA-9 images to visualise exactly where in 
the hypoxic area the m/z 400/428 band was forming (Fig. 5). The m/z 400/428 band was found to localise in the 
midst of CA-9 staining; rather than forming a boundary between hypoxic and normoxic tissue. These findings 
suggest that the lipids at m/z 400 and 428 may only be upregulated in very specific oxygen tensions. Furthermore, 
Figure 4.  2D positive ion mode DESI-MS images, overlaid with CA-9 staining for different sections of the 
GBM.
Figure 5.  Positive DESI-MS/MS of m/z 428 averaged across the image, including images of the parent and m/z 
369 fragment ion.
5Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:16512  | https://doi.org/10.1038/s41598-020-73518-x
www.nature.com/scientificreports/
the 3D positive ion mode DESI-MS image was able to visualise this metabolically unique area, allowing three 
dimensional interrogation of this heterogeneity.
Peaks observed at m/z 428 and m/z 400 have been identified as stearoylcarnitine and palmitoylcarnitine 
respectively, based on the Lipid Maps  database27 and what has been previously reported in hypoxic  areas28. In 
addition, the MS/MS spectrum for m/z 428 obtained from the tissue samples (Fig. 5), shows a fragment peak 
at 369, representative of the loss of a trimethylamine group from the carnitine. The MS/MS imaging shows that 
this fragment co-localises with the m/z 428 parent peak (Fig. 5, inset images).
Acyl-carnitines act as intermediates to shuttle fatty acids into the mitochondria. Long chain fatty acids can-
not cross the mitochondrial membranes for reasons of permeability and must be converted to fatty acyl-CoAs, 
which are in turn converted to acylcarnitines. In the mitochondria, acylcarnitines are converted back to fatty 
acyl-CoAs to undergo β-oxidation and eventually produce energy. The import into the mitochondria is the rate 
limiting step of fatty acid oxidation and is carried out by various carnitine transferases.
Lin et al. reported that fatty acid oxidation is prevalent in cells derived from human gliomas and that it plays 
an important role in proliferation. They also found that inhibition of fatty acid oxidation leads to tumour growth 
and increased survival in a syngeneic mouse glioma  model29. This finding concurs with the work of Huang et al., 
who demonstrated the importance of the hypoxia inducible factor-1α (HIF-1α) protein in inhibiting fatty acid 
oxidation at low oxygen tensions, resulting in cancer cell  proliferation30. Interestingly, we report an increase in 
β-oxidation within a subset of tumour hypoxia (relative to the normoxic regions of the U87 xenograft model), 
eluding to complex mechanisms at play within specific oxygen tensions.
Zaugg et al. discussed the role of carnitine palmitoyltransferase 1C (CPT1C), a brain-specific enzyme respon-
sible for transporting carnitines across the mitochondrial membrane. Their findings suggest that hypoxia can 
cause upregulation of CPT 1C in vivo31, in keeping with our evidence of an increase in palmitoylcarnitine in 
hypoxic regions of the U87 xenograft tumour model. These findings support the complex role of hypoxic regula-
tion of carnitines in GBM, where their upregulation at specific oxygen tensions confers a metabolic advantage 
to hypoxic cells.
Conclusion
In conclusion, we have devised a method for 3D DESI-MS imaging of a glioma model and analysed its heteroge-
neity. Automation of experiment and of 3D visualisation facilitates its use as a high throughput imaging modality 
that is suitable for large cohorts of samples. Furthermore, the use of consecutive sections allows the acquisition 
of a considerable amount of information on the biology of the tumour analysed. Despite the limitations of our 
U87 xenograft model, distinct regions of heterogeneous lipid expression that correlate with the varying levels of 
local oxygen tension and palmitoyl- and stearoyl-carnitines, appear to be playing key roles to aid β-oxidation in 
hypoxic areas of GBMs. Mapping on tissue the metabolic shift to lipid metabolism in regions with low oxygen 
tension is relevant to better understanding tumour metabolic heterogeneity in GBM and the impact of hypoxia 
on the dynamic changes of tumour microenvironment and its consequences on resistance to radiation treatment 
and  chemotherapy32–35.
Methods
Materials. Phosphate buffered saline (PBS) was made using tablets purchased from Oxoid, UK, and dis-
solved in  dH2O.
1 ml Tween (T) was added to PBS to make PBS-T. BSA (Sigma-Aldrich, UK) was dissolved at 1 mg/ml PBST 
to make PBST-BSA solution.
All solvents were purchased from Sigma-Aldrich, UK.
In‑vivo experiments. Animal experiments were conducted in accordance with the U.K. Animals (Scien-
tific Procedures) Act 1986, and had institutional and regulatory ethical approval (University of Manchester Ani-
mal Welfare and Ethical Review- AWERB) under Home Office license PPL707760 (granted to KJW). 5 × 106 U87 
cells were injected intradermally into the flank of a female cba nu/nu mice (age 10–14 weeks/weight 20–24 g). 
Mice were maintained under dawn-til-dusk 12 h light/dark cycles at an average ambient temperature of 21 °C 
(range 19–23 °C), relative humidity average 55% (range 45–65%) in pathogen free housing (Techniplast GM500 
Mouse IVC Green Line) with sterilized bedding, environmental enrichment and access to food water ad libitum 
with water supplied by Hydropac watering system. Weights, body condition and behaviour were monitored 
routinely throughout the experiments as measures of animal well-being. After 4 weeks animals were culled and 
tumours flash frozen in isopentane.
Sample preparation. A xenograft glioblastoma tumour was sectioned using a cryostat (Leica 3050 s, UK), 
and tissue sections were thaw mounted onto glass slides. Fifteen sections were taken at 120 μm steps through the 
tumour, at a 10 μm thickness for DESI-MS imaging. Serial sections (8 μm) were taken for immunofluorescence.
DESI‑MS 3D imaging. Experiments were carried out using a 2D DESI stage (Prosolia, Indianapolis,USA) 
attached to a Xevo-G2-XS quadrupole- time of flight (Q-TOF) (Waters, UK). A modified top plate of the DESI 
stage (Prior Scientific, Cambridge) was created to allow the automated PL200 microscope slide loader (Prior Sci-
entific, Cambridge) to place slides onto the stage, and then move them back to the holding cassette. A snapshot 
of the slide and object definition algorithms were used to identify the location of the tissue(s) on the slide. These 
co-ordinates were then written to the experiment file and imaging commenced. This process continued until all 
15 slides were analysed. Spatial resolution was set to 120 μm, in order to make even sized voxels. A mass range 
of m/z 50–1200 was used. Spray conditions used were 5 µl/min, 95% methanol 5% water, with a nebulising gas 
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of nitrogen at 6 bar pressure. Typical positions of the sprayer were used (sprayer 1.5 mm above surface, 6 mm 
sprayer to capillary distance, 75° sprayer impact angle, 5° collection capillary angle). Imaging was carried out in 
both negative and positive ion mode, at 10 scans/sec. The capillary voltage was 2.3 kV in negative ion mode, and 
3.42 kV in positive ion mode.
HDImaging v1.4 (Waters, Milford, USA) was used for visualisation of individual 2D images, where images 
were normalised to the total ion current (TIC). Recently developed software from Waters, UK allowed recon-
struction of the sections into a 3D image of the molecularly distinct regions within the whole tissue volume. The 
reconstruction was carried out automatically, and involved peak picking, object alignment and rotation, as well 
as a non-negative matrix factorisation (NNMF).
DESI‑MS/MS. Conditions were the same as DESI-MS imaging. MS/MS was carried out using 7 bar of argon 
gas. Lipidomics Gateway database https ://www.lipid maps.org27 was used for identification of species.
Immunofluorescence. Tissue sections were fixed in ice-cold acetone for 10 min and then left to dry. A 
DAKO pen (Agilent Technologies, UK) was used to draw around each of the sections, and 70 μl of blocking 
solution was pipetted onto each section (10% goat serum in PBST), and incubated at room temperature for 
15 min. Slides were then washed twice for 3 min in PBST-BSA. Anti-CA-9 (mouse, Biosciences, Slovakia) at 
1:1000 was made up in PBST-BSA, and 10% normal goat serum. ~ 70 μl of primary antibody solution was left on 
tissue sections at 4 °C overnight. The primary antibody solution was tapped off and the sections washed three 
times for four mins in PBS. A secondary antibody solution containing 1:100 Alexafluor 488 goat anti-mouse 
(Life technologies, UK) was prepared in PBST-BSA; and 70 μl was added to each section and left for 60 min in 
the dark at room temperature. Slides were washed again with PBS (3 × 4 min). Coverslips (VWR, UK) were then 
mounted using fluorescent mounting media (Abcam, UK). Images were acquired using a [20x/0.80 Plan Apo] 
objective using the 3D Histech Pannoramic 250 Flash II slide scanner, and processed using Panoramic viewer 
(3D HISTECH, Hungary). Images were also processed in Image  J36, where images were converted to a 32-bit 
greyscale image, and a default threshold applied.
H&E. Sections adjacent to those used for DESI-MS were stained using haematoxylin and eosin (H&E). Fol-
lowing submersion in xylene (Sigma-Aldrich, UK) for 2 min, slides were immersed 4 times for 2 min in indus-
trial methylated spirit (Sigma-Aldrich, UK). Following washing in tap water, sections were stained using Harris 
haematoxylin (3 min; Sigma-Aldrich, UK), rinsed in hot water, and dipped for one second in eosin (Leica, UK). 
Following further industrial methylated spirit (4 × 2 min) and xylene (4 × 2 min) washes, slides were left to dry. 
Samples were mounted with coverslips using aqueous mounting media (Abcam, UK) and left overnight to dry. 
Images were acquired using the 3D Histech Pannoramic 250 Flash II slide scanner with [20x/0.80 Plan Apo] 
objective and processed using Pannoramic viewer (3D HISTECH, Hungary).
Data availability
The datasets generated during and/or analysed during the current study are not publicly available as they are 
still being mined with the hope of a future publications, but are available from the corresponding author on 
reasonable request.
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